D
C4 Therapeutics, Inc. CCCC
$1.49 -$0.01-0.67% NASDAQ
Recommendation
Prev Close
$1.50
Volume
388,754
Avg Vol (90D)
1,447,157
Market Cap
$106.48M
Dividend & Yield
--
52-Week Range
$1.09 - $7.66
P/E (TTM)
--
EPS (TTM)
-$1.52
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
C4 Therapeutics (CCCC) Exceeds Revenue Expectations and Advances Key Drug Development CCCC ...
5/7/2025 - GuruFocus
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
5/7/2025 - Zacks Investment Research
C4 Therapeutics Inc (CCCC) Q1 2025 Earnings: EPS Loss of $0. ...
5/7/2025 - GuruFocus
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
5/7/2025 - GuruFocus
C4 Therapeutics reports Q1 EPS (37c), consensus (42c)
5/7/2025 - The Fly
C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
5/7/2025 - Globe Newswire
c4 therapeutics halts braf degrader work save cash cemsidomide
5/7/2025 - FierceBiotech.com - Biotech
Susquehanna Fundamental Investments LLC Acquires Shares of 108,664 C4 Therapeutics, Inc. (NASDAQ:CCCC)
5/4/2025 - Ticker Report
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
4/29/2025 - Zacks Investment Research
C4 Therapeutics, Inc. (NASDAQ:CCCC) Holdings Decreased by Lynx1 Capital Management LP
4/27/2025 - Ticker Report
C4 Therapeutics, Inc. (NASDAQ:CCCC) Shares Sold by Silverarc Capital Management LLC
4/22/2025 - Ticker Report
Wasatch Advisors LP Raises Stake in C4 Therapeutics, Inc. (NASDAQ:CCCC)
4/19/2025 - MarketBeat
Investors Don't See Light At End Of C4 Therapeutics, Inc.'s (NASDAQ:CCCC) Tunnel And Push Stock Down 40%
4/18/2025 - Simply Wall St
Contrasting C4 Therapeutics (NASDAQ:CCCC) & Invizyne Technologies (NASDAQ:IZTC)
4/15/2025 - Ticker Report
C4 Therapeutics: Getting Too Cheap To Ignore, But There's Still A Lot Of Risk Here
3/10/2025 - SeekingAlpha
C4 Therapeutics, Inc. (NASDAQ:CCCC) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough
3/4/2025 - Simply Wall St
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
3/3/2025 - Zacks Investment Research
C4 Therapeutics (NASDAQ:CCCC) Releases Earnings Results, Misses Expectations By $0.05 EPS
2/28/2025 - MarketBeat
C4 Therapeutics (NASDAQ:CCCC) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS
2/28/2025 - MarketBeat
Commit To Purchase C4 Therapeutics At $2, Earn 27.7% Annualized Using Options
2/28/2025 - Stock Options Channel
C4 Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
2/28/2025 - Simply Wall St
C4 Therapeutics Reports Strong 2024 Financial Performance and Clinical Progress
2/28/2025 - TipRanks Financial Blog
C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2/27/2025 - Zacks Investment Research
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates
2/27/2025 - Zacks Investment Research
C4 Therapeutics Inc (CCCC) Q4 2024 Earnings: EPS of -$0.49 Beats Estimate, Revenue of $5. ...
2/27/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
$35.58M
EBITDA (TTM)
-$115.36M
EBIT (TTM)
-$117.18M
Net Income (TTM)
-$105.32M
Balance Sheet
Total Assets (Q)
$349.60M
Total Debt (Q)
$65.76M
Total Liabilities (Q)
$133.62M
Book Value Per Share (Q)
$3.06
Cash Flow
Cash from Operations (TTM)
-$65.16M
Cash from Investing (TTM)
-$51.27M
Cash from Financing (TTM)
$45.34M
Net Change in Cash (TTM)
-$71.09M
Filings
Filing Date
Thursday, February 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
3.14
7-Day Total Return
-5.38%
30-Day Total Return
-19.19%
60-Day Total Return
-54.28%
90-Day Total Return
-62.63%
Year to Date Total Return
-59.15%
1-Year Total Return
-76.82%
2-Year Total Return
-53.72%
3-Year Total Return
-80.71%
5-Year Total Return
--
52-week Low
Apr 09, 2025 - $1.09
52-week High
Jul 16, 2024 - $7.66
Valuation
Market Cap
$106.48M - Micro Cap
Enterprise Value
-$63.86M
Price/Sales (TTM)
2.98
Price/Book (Q)
0.49
Dividends and Shares
Shares Outstanding
70.61M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.c4therapeutics.com
Phone Number
617 231 0700
Address
490 Arsenal Way
Watertown, MA 02472
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally... more
NASDAQ 05/08/2025 12:03PM Eastern Quotes delayed